the 21st century cures act ( p.l . 114-255 ) was signed into law on december 13 , 2016 , by president barack obama . on november 30 , 2016 , the house passed the house amendment to the senate amendment to h.r . 34 , the 21st century cures act , on a vote of 392 to 26. the bill was then sent to the senate where it was considered and passed , with only minor technical modification , on december 7 , 2016 , on a vote of 94 to 5. the law consists of three divisions : division a — 21st century cures act ; division b — helping families in mental health crisis ; and division c — increasing choice , access , and quality in health care for americans . crs has published a series of reports on this law , one on each division . this is the report for division a of the law . this report provides a brief summary of each provision of the 21st century cures act ( division a of p.l . 114-255 ) , by title , subtitle , and section . the division includes five titles , as follows : ( 1 ) innovation projects and state responses to opioid abuse ; ( 2 ) discovery ; ( 3 ) development ; ( 4 ) delivery ; and ( 5 ) savings . title i provides funding for biomedical research , including the precision medicine initiative ( pmi ) and the cancer moonshot initiative , for the opioid crisis response , and for the food and drug administration ( fda ) to support certain new activities authorized by the law . title ii , consisting of seven subtitles , requires or authorizes a number of activities to support biomedical research , including the reauthorization of the national institutes of health ( nih ) and the reform of that agency through numerous administrative , reporting , and data access provisions . the title includes provisions that support young investigators funded by nih ; pediatric research ; collaborative research such as research on neurological disease ; and precision medicine efforts , and specifically the pmi . title iii , consisting of ten subtitles , focuses on modifying the drug and device approval pathways at the fda to support innovation , and specifically includes provisions that support patient - focused drug development and streamlined and clarified pathways to approval for drugs , combination products , antimicrobials , orphan drugs , drugs for rare disease , and regenerative therapies . this title also contains provisions making modifications to the medical device approval pathway and reforms to the fda 's hiring process . finally , it addresses fda 's regulation of medical countermeasure and vaccine development . title iv focuses on health care delivery , and includes provisions that together address the federal policies to promote the adoption and use of electronic health record ( ehr ) technology , as well as a handful of medicare delivery provisions addressing telehealth services in medicare , site - of - service price transparency for certain medicare services , local coverage determinations ( lcds ) under medicare , and a technology and pharmaceutical ombudsman for medicare . title v provides savings for the division , and includes medicare and medicaid savings ; patient protection and affordable care act ( aca , p.l . 111-148 , as amended ) savings , including prevention and public health fund ( pphf ) and territory funding ; and savings from the strategic petroleum reserve ( spr ) drawdown .